The Journal of Allergy and Clinical Immunology
Volume 111, Issue 1 , Pages 87-90 , January 2003

Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma

Received 1 January 2002 ,Revised 1 January 2002 ,Accepted 1 January 2002.

  • Image Result

    Proportion of patients experiencing asthma exacerbations during the 28-week core study.

    Proportion of patients experiencing asthma exacerbations during the 28-week core study.

☆ Supported in part by Novartis Pharma AG, Basel, Switzerland, and Genentech, Inc, South San Francisco, Calif.

☆☆ Reprint requests: Jonathan Corren, MD, Allergy Research Foundation, Inc, 1160 Wilshire Blvd, Suite 200, Los Angeles, CA 90025.

PII: S0091-6749(02)91311-4

doi: 10.1067/mai.2003.49

The Journal of Allergy and Clinical Immunology
Volume 111, Issue 1 , Pages 87-90 , January 2003

Article Tools

* Image Usage & Resolution